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ABSTRACT 
 
Elastin-like peptides (ELPs) are stimulus-responsive protein-based polymers which are 
attractive material for biomedical research due to their biocompatibility and unique properties. The 
physical properties of ELPs are dependent on the chain length and the chosen amino acid at the 
guest residue position. This imparts unlimited flexibility in designing ELP based biomaterials with 
the desired physical properties.  
We have shown that in addition to their physical properties, ELPs have biological activities 
that are conducive to tissue regeneration. Specifically, we found that ELPs induce fibroblast 
proliferation via cell surface heparan sulfate proteoglycans (HSPG).  Furthermore, our data 
suggests that ELP based materials with differential proliferative potential can be designed by 
controlling the interaction of ELPs with HSPGs by incorporating either hydrophobic or positively 
charged residues within the ELP sequence. Fibroblast proliferation is important for granulation 
tissue formation which is important in chronic wounds as well as in healing of other tissues. The 
customizable biological activity of ELPs coupled with their unique physical properties will enable 
us to design novel, sustainable and cost effective therapies for different tissue regeneration 
applications.  
ELPs can be genetically fused to biologically active peptides or proteins. These fusions can 
be expressed and readily purified since they maintain the phase transitioning property of the fused 
ELP domain. Moreover, depending on the ELP sequence chosen the chimeric fusion sequences 
can self-assemble into unique structures such as nanoparticles. These structures can then be applied 
to the injury site where they not only provide unique topographical cues or structural support but 
ix 
 
also act as delivery vehicles for the fused bioactive protein. We developed a multifunctional 
nanoparticle that is comprised of PMP-D2-ELP fusion protein and different functional peptide 
ELP fusion proteins to preserve the bioactivity of the functional group with the existence of 
elastase. These heterogeneous particles will be beneficial for the delivery of combination therapies 
to solve multiple problems that often existed in chronic wound healing or other tissue regeneration 
process. 
In summary, this study adds to our understanding of the biological activity of ELP and the 
interaction mechanism that allow the regulation of cellular behavior. Furthermore this work also 
investigated the potential therapeutic application of ELP as a delivery platform for chronic wound 
healing.  
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CHAPTER 1: INTRODUCTION 
 
1.1 Skin 
Skin is the largest organ and is the outer covering of the body. It is comprised of multiple 
layers including epidermis, dermis, and hypodermis (Wilkinson 2009) (Figure 1.1). Since skin 
interfaces with the environment, it is the first line of defense against pathogens and protects the 
body from excessive water loss (Madison 2003, Proksch, Brandner et al. 2008). Other functions 
include insulation, temperature regulation, sensation, synthesis of vitamin D, and the protection of 
vitamin B folates.  
Epidermis is the outermost layer of the skin, which is about 0.2 mm. According to the 
different stages of cell development, it can be further divided to 5 layers: stratum corneum, which 
protects skin damage from friction and leakage of body fluid. Cells in this layer don’t have nuclei; 
transparent layer, which is composed of 2 to 3 layer of cells with dead nuclei, also called barrier 
zone; granular layer, which is made of flat spindle cells; prickle cell layer, in which the intercellular 
bridge is forming; and basal layer, cells in this layer constantly proliferate and gradually move up, 
keratosis, deformation, forming the other layers epidermis, finally shedding keratosis. The cycle 
for basal cells from proliferation to shedding takes about 28 days (Ovaere, Lippens et al. 2009). 
Melanocytes mixed in with the basal cells can produce melanin which determines the color of skin.  
Underneath the epidermis lies the dermis. It is mainly composed of collagen fibers, elastic 
fibers, reticular fibers which give skin certain degree of flexibility and roughness and the 
amorphous matrix and other connective tissue, of which there are nerves and nerve endings, blood 
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vessels, lymphatic vessels, muscle and skin appendages(Marks 2006). Cellular components 
include fibroblasts, histiocytes and mast cells. The thickness of the dermis and the amount of 
fibrous tissue are closely related to the density of the skin, fullness, relaxation and the wrinkling 
phenomenon. 
There is no clear boundary line between dermis and hypodermis. Hypodermis, also called 
subcutaneous adipose tissue is a layer of relatively loose organization, it is a natural cushion that 
can buffer external pressures, and it is also a heat insulator, and capable of storing energy. In 
addition to fat, subcutaneous adipose tissue is also rich in blood vessels, lymphatic vessels, nerves, 
sweat glands and hair follicles (O'Rahilly 2013). 
1.2 Wound Healing and Chronic Wounds 
Wound healing is subjected to the healing process of skin and other tissues after the break 
or defect caused by an external force. It is a complex combination of various processes including 
a variety of tissue regeneration, proliferation of granulation tissue, and scar tissue formation 
process which exhibit synergy (Stadelmann, Digenis et al. 1998, Midwood, Williams et al. 2004) 
(Figure 1.2). 
In early wounds with varying degrees of tissue necrosis and vascular rupture bleeding, 
inflammation will occur within a few hours which manifests as hyperemia, serous exudate and 
leukocyte guerrilla, and local swelling. In the early inflammation phase, neutrophils are the 
dominant cell type, while macrophage starts to take over after 2-3 days (Martin and Leibovich 
2005, de la Torre J. 2006). 
The proliferation phase starts as early as 12 hours after the initial injury. In this phase, 
fibroblasts proliferate and secrete collagen and fibronectin to form granulation tissue to fill up the 
wound gap (Stadelmann, Digenis et al. 1998). Meanwhile, vascular endothelial cells form new 
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blood vessels, a process called angiogenesis (R. 2007). Concurrently, re-epithelialization of the 
epidermis occurs, in which epithelial cells proliferate and 'crawl' atop the wound bed, providing 
cover for the new tissue (Santoro and Gaudino 2005).  
In the remodeling phase, the levels of collagen production and degradation equalize and 
start to realign. During maturation, collagen type III which is prevalent during proliferation, is 
replaced by type I collagen (C. 1999). Depending on different types of wounds, remodeling can 
last for a year or longer (Mercandetti M. 2005).  
Chronic wounds are a major source of morbidity for our aging population, affecting 6.5 
million patients in the United States annually (Daamen, Veerkamp et al. 2007). There are mainly 
three types of chronic wounds: venous stasis ulcers, diabetic foot ulcers and pressure sores. Many 
factors contribute to chronic wound formation, including ischemia, neuropathy, and repeated 
trauma (Kamoun, Landeau et al. 1995). Aging is another factor contributing to chronic wound 
formation (Mustoe 2004). Specifically, the proliferation rate of cells in the skin of old people is 
slower. Although the causes of chronic wounds vary, there are shared symptoms, such as being 
stuck in one or more phases of wound healing, such as the inflammatory stage (Snyder 2005). 
Since poor granulation and dermal remodeling are often associated with chronic wounds, 
research on treatments focuses on fibroblast proliferation and migration, such as growth factor 
therapy (Chao, Yang et al. 2012) and the use of stem cells (Devy, Duca et al. 2010).  Platelet-
derived growth factor (PDGF) is the first FDA approved biotech product for treatment of diabetic 
foot ulcers, and has been widely used clinically. However repeated direct injection of the growth 
factor is needed, and requires large amounts due to diffusion and a hostile environment in the 
wound area (Schonfelder, Abel et al. 2005).  Therefore an effective delivery method is critical for 
growth factor therapy for chronic wounds. Stem cells are undifferentiated cells that can self-
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replicate and differentiate into more specialized cells.  Studies have shown that transplanted stem 
cells derived from bone marrow and adipose tissue are conducive to chronic wound healing 
through five major paths (Crisostomo, Markel et al. 2008)- (1) increased angiogenesis, (2) 
decreased local inflammation, (3) anti-apoptotic and chemotactic signaling, (4) normalization of 
the extracellular matrix, and (5) stimulation of nearby resident stem cells.  Stem cell therapy as a 
potential treatment method for chronic wounds still needs extensive study, mainly focusing on the 
delivery mechanism, the amount of stem cells required for the treatment, and the length of time 
for the culture, expansion and characterization of the stem cells (Hu, Leavitt et al. 2015). 
1.3 Growth Factors 
Growth factors are naturally occurring substances that are capable of stimulating cell 
growth or differentiation. Wound healing is a complex biological process involving proliferation, 
differentiation and synthesis secretion of fibroblasts that enter the wound site, extracellular matrix 
fibrosis, angiogenesis, and re-epithelialization (Figure 1.3). Most growth factors that are produced 
in the process of skin wound healing have regulatory effect on one or more of processes mentioned 
above through: 1) chemotaxis, induce inflammatory cells and fibroblasts to migrate into wound 
site; 2) induce cell proliferation; 3) promote angiogenesis; 4) up-regulate the expression of 
cytokines (Bodnar 2015, Marti-Carvajal, Gluud et al. 2015). 
Platelet derived growth factor (PDGF) can be divided into a 31 KDa 7% sugar containing 
PDGF I and 28 KDa 4% sugar containing PDGF II. Both are composed of two highly homologous 
A chain and B chains, which makes the structure of PDGF dimers have three forms, i.e., PDGF-
AA, PDGF-BB and PDGF-AB. Experiments show that PDGF is an important mitogenic factor, 
which has the ability to stimulate proliferation of specific cell populations (Hannink and Donoghue 
1989, Heldin 1992). When the skin tissue is injured, formation of a blood clot will stop the bleeding. 
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At the same time, platelets release several growth factors - the most important one is the platelet-
derived growth factor. It induces fibroblasts proliferation and collagen type I and III production to 
promote the formation of granulation tissue. PDGF also helps reduce the degradation of the 
extracellular matrix by up-regulation of tissue inhibitors of metalloproteinase (TIMP-1) to inhibit 
collagenase activity. The PDGF exerts its biological effects through binding with the 
corresponding receptors on the cell membrane. PDGF receptor consists of two subunits α and β, 
having a molecular weight of 170 ~ 180 KDa (Heldin and Lennartsson 2013). The binding affinity 
of the two subunits to the A chain and B chain vary greatly. The α subunit has a good binding 
affinity to both the A chain and B chain, while the β subunit only binds to the B chain. So the α 
subunit can bind PDGF-AA, PDGF-AB and PDGF-BB, the β subunit binds only PDGF-BB and 
PDGF-AB (Matsui, Heidaran et al. 1989). 
Keratinocyte growth factor (KGF), also known as FGF-7, is a member of the fibroblast 
growth factor family. It is a basic growth factor secreted by skin tissue cells and can stimulate 
physiological metabolism processes of epithelial cells, including cell proliferation, differentiation 
and migration (Seeger and Paller 2015). Mature KGF has 163 amino acids, which have an N-
terminal glycosylation site that binds to a specific receptor on the surface of epithelial cells through 
a complex signaling process , starting to participate in gene expression and the division of epithelial 
cells , thereby stimulating epithelial tissue metabolism (Rotolo, Ceccarelli et al. 2008). 
1.4 Elastin-Like Peptides 
Elastin-like peptides are biodegradable, non-immunogenic protein-based polymers 
composed of tandemly-repeated blocks of (Val-Pro-Gly-X-Gly)N where X can be any residue, 
except Pro. This sequence motif is derived from the hydrophobic domain of tropoelastin (Urry 
1997), a soluble precursor form of elastin. An interesting property of ELPs is their ability to 
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undergo a phase transition at physiological temperatures. When the temperature is below their 
inverse transition temperature, also known as the lower critical solution temperature (LCST), they 
assume a random coil structure and are soluble in aqueous solution. However, at temperatures 
higher than the LCST, ELPs undergo an entropy driven self-assembly rendering them insoluble 
(Koria, Yagi et al. 2011) (Figure 1.4). This property enables recombinant ELPs to be expressed in 
bacteria and rapidly purified to high homogeneity using inverse temperature cycling (ITC) (Meyer 
and Chilkoti 1999).  
Due to its attractive physical properties, ELPs have been genetically fused to functional 
peptides and used in many applications. These fusions can be expressed and readily purified since 
they maintain the phase transitioning property of the fused ELP domain (Meyer and Chilkoti 1999, 
Koria, Yagi et al. 2011). Moreover, depending on the ELP sequence chosen, the chimeric fusion 
sequences can self-assemble into unique nanostructures such as nanoparticles (Osborne, Farmer et 
al. 2008, Koria, Yagi et al. 2011) or gels (Wright and Conticello 2002, Martin, Alonso et al. 2009) 
or other cross-linked materials (Srokowski and Woodhouse 2008). These nanostructures can then 
be applied to the injury site where they not only provide unique topographical cues or structural 
support but also act as delivery vehicles for the fused bioactive protein. Due to these benefits, ELPs 
have been widely used for different applications (Chilkoti, Christensen et al. 2006), including 
protein purification and separation (Bellucci, Amiram et al. 2013), drug delivery (Walker, Perkins 
et al. 2012), and scaffolds for tissue engineering (Amruthwar and Janorkar 2013). 
Even though ELPs’ physical properties have been well studied over the past decade, there 
is only limited information about its biomedical applications. Examples of the later include the use 
of cross-linked ELP based hydrogels for repair of bone defects in goats (Nettles, Kitaoka et al. 
2008) and rabbits (Hrabchak, Rouleau et al. 2010), repair of intervertebral discs in rabbits (Moss, 
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Gordon et al. 2011), investigation of biocompatibility of elastin particles using subcutaneous 
injection in rabbits (Rincon, Molina-Martinez et al. 2006), and stability of ELP peptides in blood 
(Liu, Dreher et al. 2006).  
To address this gap in our knowledge, in Chapter 2 and 3, I discussed the proliferative 
activity of ELP on fibroblasts and their interaction mechanisms. I further show that this interaction 
can be modulated by designing ELP sequences having different phase transition behavior or charge; 
thereby controlling the mitogenic activity of ELPs. Fibroblast proliferation and function is 
essential for granulation tissue formation not only in chronic wound healing but also in healing of 
injuries of other tissues such as bone or neural tissue. 
Overall this thesis gives the reader a new perspective about ELP as a potential biomaterial 
for chronic wound healing. There are several novel observations that add to existing knowledge in 
ELP applications and wound healing. For example, ELP induces fibroblasts proliferation through 
interaction with heparan sulfate proteoglycans (chapter 2). In chapter 3 I described a method for 
controlling the mitogenic activity of ELPs. A novel chronic wound model that significantly 
delayed wound healing process on diabetic mice is detailed in chapter 4. I hope this thesis is a start 
for the development of a rational framework for designing ELP based materials with the desired 
proliferative activity. The customizable biological activity of ELPs coupled with their unique 
physical properties will enable us to design novel, sustainable and cost effective therapies for 
healing of different tissues. 
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Figure 1.1 Schematic of skin. The skin consists of three major layers namely the epidermis, the 
dermis and the hypodermis. (US Gov, 2005) 
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Figure 1.2 Schematic of wound healing process. Wound healing is a complex combination of 
various processes including inflammation, proliferation, and maturation. 
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Figure 1.3 Schematic of growth factors interaction with cell. Growth factor binds to the specific 
receptor located on cell membrane and activates a series of signaling protein through 
phosphorylation.  
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Figure 1.4 Phase transition behavior of ELP. An interesting property of ELPs is their ability to 
undergo phase transition at physiological temperatures. When the temperature is below their 
inverse transition temperature, also known as the lower critical solution temperature (LCST), they 
assume a random coil structure and are soluble in aqueous solution. However, at temperatures 
higher than the LCST, ELPs undergo an entropy driven self-assembly rendering them insoluble. 
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Figure 1.5 Schematic of growth factor ELP fusion protein. 
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Figure 1.6 Cloning using recursive directional ligation. 
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CHAPTER 2: BIOACTIVITY OF ELASTIN-LIKE PEPTIDES ON FIBROBLASTS: 
PROLIFERATION AND MATRIX METALLOPROTEINASE EXPRESSION 
 
2.1 Note to Reader 
Part of this chapter was published in Yuan, Y. and P. Koria (2015). "Proliferative activity 
of Elastin-like-Peptides Depends on Charge and Phase transition." J Biomed Mater Res A. 
Permission is included in appendix B. 
2.2 Introduction 
Protein-based polymers comprised of repeating peptide sequences, where the repeating 
unit can be as few as two residues or as many as hundred residues (Urry 1997) are attractive 
biomaterials for applications of tissue regeneration (Koria 2012). Elastin like peptides are 
biodegradable, non-immunogenic protein-based polymers composed of tandemly-repeated blocks 
of (Val-Pro-Gly-X-Gly)N where X can be any residue but Pro. This sequence motif is derived from 
the hydrophobic domain of tropoelastin (Urry 1997), a soluble precursor form of elastin. An 
interesting property of ELPs is their ability to undergo a phase transition. When the temperature is 
below their inverse transition temperature, also known as the lower critical solution temperature 
(LCST), they assume a random coil structure and are soluble in aqueous solution. However, at 
temperatures higher than the LCST, ELPs undergo an entropy driven self-assembly rendering them 
insoluble (Koria, Yagi et al. 2011). This property enables recombinant ELPs to be expressed in 
bacteria and rapidly purified using inverse temperature cycling (ITC) (Meyer and Chilkoti 1999).  
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ELPs can be genetically fused to biologically active peptides or proteins. These fusions can 
be expressed and readily purified since they maintain the phase transitioning property of the fused 
ELP domain (Meyer and Chilkoti 1999, Koria, Yagi et al. 2011). Moreover, depending on the ELP 
sequence chosen the chimeric fusion sequences can self-assemble into unique structures such as 
nanoparticles (Osborne, Farmer et al. 2008, Koria, Yagi et al. 2011) or gels (Wright and Conticello 
2002, Martin, Alonso et al. 2009) or other cross-linked materials (Srokowski and Woodhouse 
2008). These structures can then be applied to the injury site where they not only provide unique 
topographical cues or structural support but also act as delivery vehicles for the fused bioactive 
protein. Due to these benefits, ELPs have been widely used for several biomedical applications 
(Chilkoti, Christensen et al. 2006), including protein purification and separation (Bellucci, Amiram 
et al. 2013) and drug delivery (Walker, Perkins et al. 2012). 
The physical properties of ELPs are dependent on the chain length and the chosen amino 
acid at the guest residue position (Urry 1997). This imparts unlimited flexibility in designing ELP 
based biomaterials with the desired physical properties. Elegant work by several researchers has 
elucidated the role of sequential variations on the physical properties of ELPs (Meyer and Chilkoti 
2004, Trabbic-Carlson, Meyer et al. 2004, Cho, Zhang et al. 2008, Ribeiro, Arias et al. 2009, Jeon 
2011). This has provided further insights and design rules that have to be followed to develop ELP 
based biomaterials with the desired physical properties and molecular structure. For example, 
substitution of a more hydrophobic amino acid at the guest residue position or increase in the chain 
length yields a polymer with a reduced transition temperature (Meyer and Chilkoti 2004). 
Additionally, Chilkoti and co-workers have described the formation of micellar nanoparticles 
using a block co-polymer comprised of two ELPs with different transition temperatures (Dreher, 
Simnick et al. 2008). Moreover, the formation of ELP based hydrogels has also been described by 
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selection of unique ELP sequences (Wright and Conticello 2002, Srokowski and Woodhouse 2008, 
Martin, Alonso et al. 2009).  
However, the biological characterization of ELPs is missing in all of the aforementioned 
studies. Very few studies have reported the implantation and effects of ELP based biomaterials in 
vivo. These include the use of cross-linked ELP based hydrogels for repair of bone defects in goats 
(Nettles, Kitaoka et al. 2008) and rabbits (Hrabchak, Rouleau et al. 2010), repair of intervertebral 
disc in rabbits (Moss, Gordon et al. 2011), investigation of biocompatibility of elastin particles 
using subcutaneous injection in rabbits (Rincon, Molina-Martinez et al. 2006) and stability of ELP 
peptides in blood (Liu, Dreher et al. 2006). All of these have reported that ELPs are biocompatible, 
well tolerated and do not induce inflammation. Nevertheless, these studies mainly focused on the 
mechanical strength of the ELP hydrogels and their application was mainly limited as providers of 
mechanical support within the defect. While, some effects on chondrocytes proliferation were 
observed but there was no detailed mechanistic investigation or report of any possible biological 
activity of ELPs within the injury environment. Since, elastin is an integral part of the extracellular 
matrix elastin derived peptides (EDPs) or ELPs may affect certain cellular functions. Indeed, EDPs 
which are elastin breakdown peptide products have been shown to modulate cellular behavior of 
a variety of cell types such as fibroblasts and monocytes (Senior, Griffin et al. 1984), hepatocytes 
(Janorkar, Rajagopalan et al. 2008), smooth muscle cells (Mochizuki, Brassart et al. 2002), 
endothelial cells (Faury, Garnier et al. 1998) and keratinocytes (Fujimoto, Tajima et al. 2000). 
Specifically in fibroblasts that play a key role in regeneration, EDPs have been shown to induce 
proliferation and expression of several matrix remodeling proteins such as collagenase (Brassart, 
Fuchs et al. 2001, Duca, Debelle et al. 2002). However, in these experiments the precise molecular 
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weights and sequences that induce effects on cells is not known since the degradation product is a 
complex mixture of several elastin peptides having different sequences and molecular weight. 
Here, we created several ELPs with precise sequences and molecular weight and evaluated 
their biological activity. We found that ELPs induced proliferation and matrix metalloproteinase 
1 (MMP1) expression in fibroblasts which both are crucial for tissue regeneration process.  We 
further report that these two activities were a result of interaction with two different molecules 
present on the cell surface. 
2.3 Materials and Methods 
2.3.1 Materials  
Human dermal fibroblasts (CRL-2522) were purchased from ATCC (Manassas, VA). PBS, 
FBS and DMEM were all purchased from life technologies. The restriction enzymes used for 
cloning were purchased from New England Biolabs (Ipswich, MA). The reagents for RT-PCR 
were purchased from Bio-Rad. BrdU cell proliferation assay kit was purchased from BD 
Pharmingen. Miniprep kit and gel extraction kit used for sub cloning process were purchased from 
Qiagen. 
2.3.2 Generation of ELP Plasmids and Expression of the Protein 
The PUC57 plasmids containing the elastin cassette (VPGVG)5 and 
(VPGVG)2VPGCG(VPGVG)2 were purchased from Genscript (Piscataway, NJ). V40C2 and V50 
encoding genes were made using recursive direction ligation method as described previously 
(Meyer and Chilkoti 2002). PUC19-C plasmid was used as template in site-directed mutagenesis 
for the generation of (VPGVG)2 VPGLG (VPGVG)2, (VPGVG)2 VPGKG (VPGVG)2 and 
(VPGVG)2 VPGDG (VPGVG)2 cassette. L10 and K10 encoding gene were made using same 
method mentioned above. 
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The expression vector pET25b+ was digested with SfiI and dephosphorylated. Ligation 
was performed using linear pET25b+ vector and respective ELP encoding gene cassettes.  E.coil 
BLR cells were transformed with expression vector with ELP encoding genes. For protein 
production, a starter culture of 75ml terrific broth medium was inoculated overnight and added to 
1L culture the next day. After 16hrs of induction, bacterial cells were harvested by centrifugation 
at 40C, re-suspended in ice cold phosphate buffered saline (PBS). Cells were lysed on ice using 
sonication. Cell debris was removed by centrifugation at 40C followed by polyethyleneimine 
treatment (final concentration: 0.5% w/v) for DNA precipitation. After another centrifugation at 
40C, the clear supernatant was heated up to 400C in water bath for 15min to transition the ELPs 
followed by centrifugation at 400C to pellet the ELPs. The ELP pellet was then dissolved in ice 
cold PBS followed by centrifugation at 40C to remove the insoluble impurities. This hot and cold 
spin cycle was then repeated twice for a total of three cycles. The final protein pellet was dissolved 
in deionized water and dialyzed overnight. The protein was then lyophilized and stored in a 
desiccator. 
2.3.3 BrdU Cell Proliferation Assay 
Human skin fibroblasts were cultured in 10 cm cell culture plates with 10% fetal bovine 
serum (Invitrogen, Grand Island, NY). 100,000 cells were plated in 6-well plate and were allowed 
to attach for 24 hours. After 24 hours, the cells were serum starved for another 24 hours followed 
by treatment with different ELPs for 48 hours. New DNA synthesis was quantified using the BrdU 
cell proliferation kit (BD Pharmingen, San Jose, CA) according to the manufacturer’s instruction. 
Briefly, cells were treated with BrdU for 24 hours. After 24 hours the cells were fixed and stained 
using a fluorescently tagged BrdU antibody. Then cells were stained with 7-AAD for cell cycle. 
BrdU incorporation in the cells was evaluated using flow cytometry.  
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 To explore the signaling pathways involved in ELP induce proliferation the plated cells 
were pre-incubated for 1hr with the following inhibitors: (i) 5mM of lactose to block elastin 
binding protein, (ii) 10µM of PD98059 to inhibit MAPK, (iii) 100nM of wortmannin to inhibit 
PI3K, (iv) 20mIU/ml of Heprinase III or 10µM of surfen to block hepran sulfate activity. Each 
concentration of inhibitor was chosen based on previous studies (Schuksz, Fuster et al. 2008, 
Rusciani, Duca et al. 2010, Nikmanesh, Shi et al. 2012, Huang, Sun et al. 2013). ELPs were then 
added to the cells in the presence of different inhibitors. After 48hrs, new DNA synthesis was 
quantified using the Brdu cell proliferation assay as described above. 
2.3.4 Crosslinking of Surface Immobilized and Free ELP  
Maleimide Activated Plates (Pierce, Waltham, MA) were used to immobilize the 
sulfhydryl-containing ELP (V40C2).  Plate wells were washed three times with 200µL wash buffer 
(0.1M sodium phosphate, 0.15M sodium chloride, 0.05% Tween®-20 Detergent; pH 7.2).  V40C2 
sodium chloride, 10mM EDTA; pH 
7.2) was prepared and 100-150µL of the ELP solution was added to each well and incubated 
overnight at 4°C with continuous mixing. Next day before use, wells were washed three times 
(200µL of Wash Buffer/wash) followed by cell plating for the proliferation experiment described 
above. ELP with His tag was used to detect successful immobilization with anti-His antibody 
(Sigma, St. Louis, MO) using ELISA. 
Free ELP was crosslinked by oxidation using 3% hydrogen peroxide. 3% hydrogen 
peroxide was added in 50µM ELP solution and incubated for 1hr at room temperature with 
continuous shaking. The crosslinked ELP was purified from the peroxide by centrifugation at 400C 
for 10 minutes. 
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2.3.5 Flow Cytometry for ELP Internalization 
The cysteines in the ELP (V40C2) were labeled with fluorescein conjugated maleimide 
(Invitrogen, Grand Island, NY). ELPs were incubated with the maleimide overnight at 4 0C. The 
labeled ELPs were purified from the excess fluorescein tagged maleimide by 1 cycle of inverse 
temperature cycling. Fibroblasts were treated with the labeled ELPs for 24 hours. The cells were 
then washed 3 times with ice cold PBS. Cells were trypsinized from the wells pelleted and 
incubated with Trypan blue for 15 minutes to quench the fluorescence on the cell surface. The 
internalization of the labeled ELP was evaluated by quantifying the fluorescence per cell using 
flow cytometry.  
2.3.6 Dynamic Light Scattering 
 Lyophilized protein samples were resuspended in PBS at desired concentration and then 
filtered through 0.22µm syringe filter. 1ml filtered sample solution in cuvette was read in dynamic 
light scattering (DLS) (Zetasizer Nano S, Malvern, UK) using a temperature trend analysis from 
30˚C to 42˚C at a step of 2˚C. An equilibrium time of 10 min and 3 readings were performed in 
each temperature point. 
2.3.7 Real Time PCR for Gene Expression  
Fibroblasts (80,000 cells/well) were plated in 6-well plate and then lysed for RNA isolation 
after 48hrs of ELP treatments. The RNA from these cells was isolate using the Total RNA isolation 
kit (Promega, Madison, WI) as per manufacture recommendations. cDNA was synthesized from 
total cellular RNA using the iScrpt cDNA synthesis kit (Biorad, Ipswich, MA). Briefly, 50 ng of 
total RNA was reverse transcribed in a 20μL volume containing 5μL 4× RT reaction mix (Biorad) 
and 1μL enzyme for 5 minutes at 25 0C, followed by 30 minutes at 42 0C. The cDNA was then 
incubated at 85 0C for 5 minutes. Quantitative real-time PCR was performed using the SsoFast 
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EvaGreen supermix (Biorad). The primers used to detect MMP-1 were 5’-
AGTGACTGGGAAACCAGATGCTGA-3’ and 5’-GCTCTTGGCAAATCTGGCCTGTAA-3’. 
The primers used to detect GAPDH were 5’-CCTGCACCACCAACTGCTTA-3’ and 5’-
GCCTGCTTCACCACCTTCTT-3’. The quantitative analysis was done using Biorad CFX 
manger. 
2.3.8 Animals 
The mouse strain that we have chosen is B6.BKS-Leprdb from Jackson Laboratories. 
These mice are homozygous for the diabetes spontaneous mutation (Leprdb) and become 
identifiably obese around 3 to 4 weeks of age. They exhibit elevations of plasma insulin at 10 to 
14 days and of blood sugar at four to eight weeks. Moreover, wound healing in these mice is 
delayed. Hence, it is a good and well accepted model to study chronic diabetic wounds in the 
research community.  
2.3.9 Excisional Wounding of Skin 
Mice will be anesthetized using Isoflurane inhalation (3-4% induction, 1-2% maintenance) 
on a heating pad at 37˚C and anesthesia deemed sufficient when the animal lacks a contracting 
reflex in response to interdigital pinch and palpebral/eyeblink reflex. The eyes of the animal will 
be covered with medical ointment to prevent dryness. Hair will be removed from the dorsal area 
using electric clippers in an area away from the surgical site. The anesthetized animal would then 
be brought to the surgical site and the dorsum will be prepared by a three-fold alternating 
application of Betadine SCRUB and 70% alcohol solution. A 1cm x 1cm square area will be drawn 
with a black marker on the back of the animal using a template. The skin will be gently lifted up 
and cut along the marked boundary to generate a full-thickness skin defect on the dorsum. 100µl 
of fibrin gel containing different treatments will be administered into the wounds. The mice will 
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then be dressed with a 2.5 cm x 2.5 cm piece of adherent silicone dressing (Tegaderm™) 
encompassing an area extending at least 1 cm beyond the wound boundaries. Animals will be 
single caged after the procedures and standard bedding will be used.  
2.3.10 Post Procedure Observations 
Animals will be under continuous examination until they recover from the anesthesia as 
evidenced by the ability to maintain themselves in an upright position, and by assessment of the 
respiratory rate and response to visual, acoustic, and touch stimuli. Then, they will be returned to 
the animal housing area. After housing, animals will be observed every 12 hours for 72 hours then 
daily till 28 days. Animals with be euthanized at 14 days post wounding and tissue surrounding 
the wound area (including the wound) will be excised and collected for histological analysis. 
2.3.11 Statistical Analysis 
Cell proliferation assay results were expressed as normalized mean ± SEM to control. 
Statistical significance of the observed differences was evaluated by ANOVA: single factor 
whereas p value < 0.05 were considered significant (n=3). 
2.4 Results 
2.4.1 ELPs Induce Proliferation of Human Skin Fibroblasts  
We have recently shown that a fusion protein comprising of ELP and growth factor retains 
the bioactivity of the growth factor and physical phase transition of the ELP (Koria, Yagi et al. 
2011). This fusion protein was successful in healing of diabetic wounds. Interestingly, ELPs by 
themselves induced significant granulation (Koria, Yagi et al. 2011) (Figure 2.2). This was a 
surprising result that warranted further attention as several studies involving ELPs in animal 
models have reported that ELPs are biologically inert and exhibit no significant biological activity 
(Nettles, Kitaoka et al. 2008, Hrabchak, Rouleau et al. 2010). Since fibroblasts are the main cells 
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responsible for granulation we reasoned that ELPs may affect fibroblast functions particularly 
proliferation. Therefore, we used human dermal fibroblasts to evaluate whether ELPs induced 
proliferation in these cells. Indeed, ELPs increased proliferation of dermal fibroblasts as high as 
4.7 folds at a treatment of 50 M of ELP (Figure 2.3). Since, increasing of ELPs concentration 
beyond 50 M did not increase fibroblast proliferation significantly; we decided to use a 
concentration of 50 M for subsequent experiments.  
2.4.2 Immobilization or Crosslinking Leads to Loss of Proliferative Potential of ELPs 
Previous experiments investigating the ELP bioactivity used either crosslinked ELPs or 
ELP immobilized on a solid surface (Nettles, Kitaoka et al. 2008). We reasoned that this could be 
a possible reason why previous studies did not report any proliferative activity of ELPs. To test 
this hypothesis we immobilized ELP on a cell culture plate using maleimide chemistry. 
Immobilized ELPs did not induce cell proliferation (Figure 2.4a) thereby confirming the 
hypothesis that immobilization of ELPs leads to loss in their proliferative activity. However, the 
loss in proliferative activity could also be attributed to the inability of cells to uptake the 
immobilized ELPs. To eliminate this possibility we cross-linked free ELP particles using hydrogen 
peroxide. The cross-linked ELP particles were free to move in the solution but were unable to 
induce proliferation in fibroblasts (Figure 2.5a). Finally, we further show that ELPs that induce 
proliferation in fibroblasts are not uptaken by them (Figure 2.6). Thus, these data show that 
internalization of ELPs is not necessary for their proliferative activity.  
2.4.3 ELP Induced Matrix Metalloproteinase Induction via Elastin Receptor 
Previous research has demonstrated that the GXXPG motif contained in tropoelastin 
induces pro-MMP1 expression (Moroy, Alix et al. 2005). Since ELP has the similar sequence 
motif VPGXG, we tested the induction of MMP1 gene by ELPs in fibroblasts using quantitative 
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real time polymerase chain reaction (qRT-PCR). Indeed similar to elastin derived monomeric 
peptides, ELP significantly induced MMP1 expression in fibroblasts (Figure 2.7a).  Interestingly, 
lactose blocked the ELP induced MMP1 expression suggesting the involvement of the elastin 
receptor in MMP1 induction unlike proliferation. Furthermore, we investigated the effect of phase 
transition or charges in the induction of MMP-1 by ELPs. We found that the monomer VPGVG 
induced MMP1 induction suggesting that it is independent of the phase transition property of ELPs 
(Figure 2.7b).  
2.4.4 ELP Accelerated the Wound Closure and Re-epithelialization in vivo 
 Fibroblasts play a crucial role in chronic wound healing. Since ELP induced fibroblast 
proliferation may be beneficial for wound healing, we also tested how ELP perform as a potential 
therapeutic for wound healing in diabetic mice wound model. Interestingly, we found that indeed 
ELP promoted wound healing process, within 14 days complete wound closure was observed with 
significant faster re-epithelialization comparing to control. Mice treated with PDGF-ELP fusion 
protein as a positive control were also observed complete wound closure in 14 days (Figure 2.8).  
2.5 Discussion 
Current research on biomaterials mostly describes inert biomaterials that provide 
mechanical support or act as drug delivery vehicles carrying an active drug for tissue regeneration. 
The bioactivity of the biomaterials is typically achieved by the inclusion of an active drug or an 
active sequence that induces cellular response. However, our work suggests that the biomaterial 
backbone (VPGXG) is also capable of inducing fibroblast proliferation with no active biological 
signal embedded within. Thus, ELP based biomaterials are not only capable of providing 
mechanical support but also have biological activities conducive to fibroblast proliferation which 
is crucial for healing of different tissues.  
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 Elastin derived peptides that are prepared by proteolytic degradation of -elastin or elastin 
based tissues have been shown to increase proliferation of arterial smooth muscle cells (Mochizuki, 
Brassart et al. 2002) and fibroblasts (Shiratsuchi, Ura et al. 2010) respectively. Since, these studies 
were done using a complex mixture of degradation products of elastin, the exact sequence or 
molecular weight of the species that induced proliferation could not be identified. On the other 
hand our work reports the induction of proliferation by a single elastin sequence with precise 
molecular weight, thus allowing us to identify the exact sequence responsible for proliferation. 
Our work indicates that the model sequence (VPGVG)50 induced fibroblast proliferation. However, 
previous work has reported that the monomeric or polymeric form of this model sequence VPGVG 
created by solid peptide synthesis did not demonstrate any significant proliferative activity on 
fibroblasts (Tajima, Wachi et al. 1997). This could be attributed to the very low concentrations of 
ELP used in that study compared to our experiments. The concentration of ELP is directly related 
to their transition behavior, which seems to be critical for inducing fibroblast proliferation as 
demonstrated by our experiments. 
The observed mitogenic activity of ELPs is lost due to crosslinking or when they are 
immobilized on a solid substrate. This result explains why previous work performed with ELP 
hydrogels report no significant biological activity; since it involved chemically cross-linked ELP 
hydrogels leading to the loss of the mitogenic activity of ELPs (Nettles, Kitaoka et al. 2008, 
Hrabchak, Rouleau et al. 2010). Interestingly, the inability of the cells to internalize the cross-
linked ELP will not explain the loss in bioactivity since the induced proliferation was independent 
of ELP internalization. Crosslinking results in loss of ability of ELPs to toggle between aggregates 
or single monomeric forms, which may lead to the loss of the biological activity. Further studies 
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are needed to investigate the exact role of cross-linking and its effect on the biological activity of 
ELPs.   
In summary, our work demonstrates that the biological activity of ELPs can be modulated 
by simply tweaking their physical properties. Specifically, we show for the first time that ELPs 
induce fibroblast proliferation which is dependent on cell surface HSPGs. Fibroblast proliferation 
and function is essential for granulation tissue formation in not only chronic wound healing but in 
healing of injuries of other tissues such as bone or neural tissue. Thus, ELP based materials with 
differential proliferative activity on fibroblasts can be designed and will have broad application in 
the development of therapeutics for tissue regeneration. 
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Figure 2.1(a) ELP purification and characterization: protein stain. ELPs were purified using 
inverse temperature cycling. The bacterial lysate and purified ELP was run on a SDS-PAGE gel 
and stained with simply safe blue stain for total protein. Lane 1, bacteria lysate; lane 2, purified 
ELP (V40C2).  
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Figure 2.1(b) ELP purification and characterization: dynamic light scattering. Scattered light 
intensity as a function of temperature. 
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Figure 2.2 ELP enhances granulation tissue formation in diabetic mice wound.(Koria, 2010) 
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Figure 2.3 ELPs induce fibroblast proliferation. Cells were serum starved for 24hrs then treated 
for 48 hrs with the indicated concentrations of ELPs. BrdU assay was performed for cell 
proliferation as described in materials and methods. All the values are obtained from triplicate 
experiments and normalized to control. * = p< 0.05. 
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Figure 2.4(a) Immobilized ELP didn’t induce fibroblast proliferation. Cell proliferation assay was 
performed in the plates containing cysteine immobilized ELPs (V40C2) by maleimide chemistry 
as described in the text. Non cysteine containing ELP (V50) was used as a control. Cells were 
cultured on ELP containing plates for 48 hours and proliferation was evaluated using the BrdU 
assay. *=p<0.05. 
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Figure 2.4(b) Immobilization of ELP on cell culture plate. Elisa shows His-tag V40C2 was 
successful immobilized in maleimide plate. 
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Figure 2.5(a) Crosslinked ELP didn’t induce fibroblast proliferation. Cells were starved for 24hrs 
and then treated with 50 M of crosslinked V40C2 for 48hrs. BrdU assay was performed for cell 
proliferation. All the values are obtained from triplicate experiments and normalized to control. 
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Figure 2.5(b) Successful crosslinking of ELP was detected by monitoring the absorbance in PBS 
at 350 nm as a function of temperature. 
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Figure 2.6 ELP was not internalized by fibroblasts. Cells were treated with FITC labeled ELP for 
24hrs and ELP internalization was evaluated by flow cytometry. 
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Figure 2.7(a) ELPs induce MMP1 expression is independent of phase transition property of ELP. 
Cells were serum starved for 24hrs and then treated with 50 M of ELPs and penta-peptide 
VPGVG. 
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Figure 2.7(b) ELPs induce MMP1 expression in fibroblasts through elastin receptor. Cells were 
serum starved for 24hrs and then treated with 50 M of ELPs and pentapeptide VPGVG with or 
without lactose. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
42 
 
 
Figure 2.8 ELP accelerated the wound closure and re-epithelialization in vivo. 1 cm ×1 cm full 
thickness wound was created on the dorsal area of the mouse. Either ELP or PDGF-ELP was 
treated on the wound. Animals with be euthanized at 14 days post wounding and tissue surrounding 
the wound area (including the wound) will be excised and collected for histological analysis. 
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CHAPTER 3: PROLIFERATIVE ACTIVITY OF ELASTIN-LIKE PEPTIDES DEPENDS 
ON CHARGE AND PHASE TRANSITION 
3.1 Note to Reader 
Part of this chapter was published in Yuan, Y. and P. Koria (2015). "Proliferative activity 
of Elastin-like-Peptides Depends on Charge and Phase transition." J Biomed Mater Res A. 
Permission is included in appendix B. 
3.2 Introduction 
Heparan sulfate proteoglycan (HSPG) is widely distributed in the cell membrane and 
extracellular matrix of animal tissues. It plays a crucial role in body development and physiological 
balance maintenance (Iozzo 1998, Gallagher 2000). Polysaccharide heparan sulfate chains unique 
molecular structure makes this kind of macromolecular complexes with a variety of biological 
functions which is achieved mainly through the implementation of the ligand and protein 
(Williams and Fuki 1997). HSPG on cell surface mediate a variety of cellular activity factors 
binding with their receptors, participating in signal transduction processes (Guimond, Maccarana 
et al. 1993, Feyzi, Lustig et al. 1997, Mitsi, Forsten-Williams et al. 2008, Gutierrez and Brandan 
2010). It is also an important part of intercellular substance, and maintain the stability of interstitial 
structure along with collagen. 
 HSPG can be divided to four different categories, including glypican, syndecan, perlecan 
and agrin. Glypican and syndecan are located on the cell membrane, while perlecan and agrin are 
secretive HSPG that found in intercellular substance and basement membrane (Sarrazin, Lamanna 
et al. 2011). Syndencan family consists of four members (Sdc-1 ~ Sdc-4), although the molecular 
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weight of each member is different (22 ~ 45 kD), but they all have an intracellular portion (C -
terminus), a transmembrane region and extracellular domain (N -terminal) as structural 
components (Bernfield, Kokenyesi et al. 1992, Carey 1997). Extracellular domain sequence of 
four members vary greatly, but commonly they all have heparan sulfate and chondroitin sulfate 
modification sites. At present, for syndecan associated expression and physiological function are 
not completely understood, but existing research results suggest syndecan plays an important role 
in the regulation of body development process. Sdn-1 is dominant in endothelial cells, participating 
in angiogenesis, wound healing and the interactions between leukocytes and endothelial cells (Abu 
El-Asrar, Nawaz et al. 2014, Andersen, Kristensen et al. 2015). Sdn-2 expresses in the kidney, 
lung and gastric stromal cells, cartilage and osteoblasts (Munesue, Kusano et al. 2002, Vicente, 
Ricci et al. 2013, Mansouri, Hay et al. 2015). Sdn-3 mainly exists in the nerve cells and is the co-
receptor of Agouti related peptide (AGRP) which regulate feeding behavior by binding to 
melatonin receptors (Reizes, Benoit et al. 2003, Creemers, Pritchard et al. 2006). Sdn-4 is widely 
present in the embryonic development process, and also in most mature body tissue, but in low 
expression (Suga, Sugimura et al. 2012). The main function of sdn-4 is to adjust the structure of 
matrix and cell adhesion (Carey 1997, De Luca, Klimentidis et al. 2010). 
 Elastin is a major component in skin dermis which gives the skin tissue the elasticity and 
tensile capacity. Elastin derived peptide (EDP), peptide products resulting from degradation of -
elastin has been shown to modulate cellular behavior of a variety of cell types such as fibroblasts 
and monocytes (Senior, Griffin et al. 1984), hepatocytes (Janorkar, Rajagopalan et al. 2008), 
smooth muscle cells (Mochizuki, Brassart et al. 2002), endothelial cells (Faury, Garnier et al. 1998) 
and keratinocytes (Fujimoto, Tajima et al. 2000). Specifically in fibroblasts that play a key role in 
regeneration, EDPs have been shown to induce proliferation and expression of several matrix 
49 
 
remodeling proteins such as collagenase (Mochizuki, Brassart et al. 2002, Dorecka, Francuz et al. 
2014). Study haven shown that the activity of EDP on cells are achieved through interaction with 
elastin receptor complex, which is composed of three subunits, elastin binding protein, 
neuraminidase, and cathepsin A (Hance, Tataria et al. 2002). Two downstream signaling pathways 
are associated with the activation of elastin receptor, Erk1/2 and PI3K (Duca, Lambert et al. 2005, 
Chao, Yang et al. 2012, Shi, Wang et al. 2012). MAPK/Erk is a Ser/Thr protein kinases. When 
MEK is activated, it connects directly to Erks through its N-terminus. MEK is also the anchor for 
Erk in cytoplasm. When there is no active signal, MEK fixes Erk in the cytoplasm, once Erk is 
phosphorylated and dimerized, MEK will transfer it into nucleus or other activation site for the 
further phosphorylation of downstream substrates (Avruch, Khokhlatchev et al. 2001). Wilsbacher 
et al. studied the translocation process of phosphorylated Erk2 into nucleus, and found that the 
translocation of Erk2 is dependent on the formation of homodimers between a phosphorylated 
Erk2 and another Erk2, either phosphorylated or un-phosphorylated, which suggested that the 
formation of homodimer is critical for Erk2 translocation into nucleus (Wilsbacher, Juang et al. 
2006). PI3K pathway is another intracellular signaling pathway that is important in regulating the 
cell cycle. Phosphorylation of PI3K activates AKT which locates in the plasma membrane. Many 
factors are known for enhancing PI3K/AKT pathway including EGF, shh, IGF-1, insulin, and 
CaM(Ju, Liao et al. 2015, Li, Hu et al. 2016, Zheng, Ye et al. 2016). 
3.3 Materials and Methods 
3.3.1 Materials  
Human dermal fibroblasts (CRL-2522) were purchased from ATCC (Manassas, VA). PBS, 
FBS and DMEM were all purchased from life technologies. The restriction enzymes used for 
cloning were purchased from New England Biolabs (Ipswich, MA). The reagents for RT-PCR 
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were purchased from Bio-Rad. BrdU cell proliferation assay kit was purchased from BD 
Pharmingen. 
3.3.2 Generation of ELP Plasmids and Expression of the Protein 
The PUC57 plasmids containing the elastin cassette (VPGVG)5 and 
(VPGVG)2VPGCG(VPGVG)2 were purchased from Genscript (Piscataway, NJ). V40C2 and V50 
encoding genes were made using recursive direction ligation method as described previously 
(Meyer and Chilkoti 2002). PUC19-C plasmid was used as template in site-directed mutagenesis 
for the generation of (VPGVG)2 VPGLG (VPGVG)2, (VPGVG)2 VPGKG (VPGVG)2 and 
(VPGVG)2 VPGDG (VPGVG)2 cassette. L10 and K10 encoding gene were made using same 
method mentioned above. 
The expression vector pET25b+ was digested with SfiI and dephosphorylated. Ligation 
was performed using linear pET25b+ vector and respective ELP encoding gene cassettes.  E.coil 
BLR cells were transformed with expression vector with ELP encoding genes. For protein 
production, a starter culture of 75ml terrific broth medium was inoculated overnight and added to 
1L culture the next day. After 16hrs of induction, bacterial cells were harvested by centrifugation 
at 40C, re-suspended in ice cold phosphate buffered saline (PBS). Cells were lysed on ice using 
sonication. Cell debris was removed by centrifugation at 40C followed by polyethyleneimine 
treatment (final concentration: 0.5% w/v) for DNA precipitation. After another centrifugation at 
40C, the clear supernatant was heated up to 400C in water bath for 15min to transition the ELPs 
followed by centrifugation at 400C to pellet the ELPs. The ELP pellet was then dissolved in ice 
cold PBS followed by centrifugation at 40C to remove the insoluble impurities. This hot and cold 
spin cycle was then repeated twice for a total of three cycles. The final protein pellet was dissolved 
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in deionized water and dialyzed overnight. The protein was then lyophilized and stored in a 
desiccator. 
3.3.3 BrdU Cell Proliferation Assay 
Human skin fibroblasts were cultured in 10 cm cell culture plates with 10% fetal bovine 
serum (Invitrogen, Grand Island, NY). 100,000 cells were plated in 6-well plate and were allowed 
to attach for 24 hours. After 24 hours, the cells were serum starved for another 24 hours followed 
by treatment with different ELPs for 48 hours. New DNA synthesis was quantified using the BrdU 
cell proliferation kit (BD Pharmingen, San Jose, CA) according to the manufacturer’s instruction. 
Briefly, cells were treated with BrdU for 24 hours. After 24 hours the cells were fixed and stained 
using a fluorescently tagged BrdU antibody. BrdU incorporation in the cells was evaluated using 
flow cytometry.  
 To explore the signaling pathways involved in ELP induce proliferation the plated cells 
were pre-incubated for 1hr with the following inhibitors: (i) 5mM of lactose to block elastin 
binding protein, (ii) 10µM of PD98059 to inhibit MAPK, (iii) 100nM of wortmannin to inhibit 
PI3K, (iv) 20mIU/ml of Heprinase III or 10µM of surfen to block heparan sulfate activity. Each 
concentration of inhibitor was chosen based on previous studies (Schuksz, Fuster et al. 2008, 
Rusciani, Duca et al. 2010, Nikmanesh, Shi et al. 2012, Huang, Sun et al. 2013). ELPs were then 
added to the cells in the presence of different inhibitors. After 48hrs, new DNA synthesis was 
quantified using the BrdU cell proliferation assay as described above. 
3.3.4 Dynamic Light Scattering 
 Lyophilized protein samples were resuspended in PBS at desired concentration and then 
filtered through 0.22µm syringe filter. 1ml filtered sample solution in cuvette was read in DLS 
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(Zetasizer Nano S, Malvern, UK) using a temperature trend analysis from 30˚C to 42˚C at a step 
of 2˚C. An equilibrium time of 10 min and 3 readings were performed in each temperature point. 
3.3.5 Real Time PCR for Gene Expression 
Fibroblasts (80,000 cells/well) were plated in 6-well plate and then lysed for RNA isolation 
after 48hrs of ELP treatments. The RNA from these cells was isolate using the Total RNA isolation 
kit (Promega, Madison, WI) as per manufactures’ recommendations. cDNA was synthesized from 
total cellular RNA using the iScrpt cDNA synthesis kit (Biorad, Ipswich, MA). Briefly, 50 ng of 
total RNA was reverse transcribed in a 20-μL volume containing 5μL 4× RT reaction mix (Biorad) 
and 1μL enzyme for 5 minutes at 25 0C, followed by 30 minutes at 42 0C. The cDNA was then 
incubated at 85 0C for 5 minutes. Quantitative real-time PCR was performed using the SsoFast 
EvaGreen supermix (Biorad). The primers used to detect MMP-1 were 5’-
AGTGACTGGGAAACCAGATGCTGA-3’ and 5’-GCTCTTGGCAAATCTGGCCTGTAA-3’. 
The primers used to detect GAPDH were 5’-CCTGCACCACCAACTGCTTA-3’ and 5’-
GCCTGCTTCACCACCTTCTT-3’. The quantitative analysis was done using Biorad CFX 
manager. 
3.3.6 Statistical Analysis 
Cell proliferation assay results were expressed as normalized mean ± SEM to control. 
Statistical significance of the observed differences was evaluated by ANOVA: single factor 
whereas p value < 0.05 were considered significant (n=3). 
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3.4 Results 
3.4.1 ELPs Induced Proliferation of Fibroblasts Is Mediated through Cell Surface Heparan 
Sulfate Proteoglycans 
ELPs are attractive biomaterials as their physical properties are tunable by sequence 
modification. We hypothesized that similar to the physical properties of ELPs the proliferative 
potential of ELPs can also be controlled via sequence modification. This can be achieved by 
modulating the ELP-cell interactions that lead to ELP mediated cell proliferation. Hence, we need 
to identify the interaction partners of ELPs present on the cell surface that lead to ELP mediated 
proliferation. Since, previous studies have shown that elastin derived peptides modulate cellular 
functions via the elastin receptor (Duca, Blanchevoye et al. 2007), we first targeted this receptor. 
Lactose sugar binds to the elastin receptor thereby shedding it from the cell surface. Thus, we 
carried out the proliferation experiments in the presence of lactose. The increase of fibroblast 
proliferation mediated by ELPs remained unaffected by the presence of lactose (Figure 3.1). 
Moreover, it has been reported that ELPs activate the ERK ½ MAP Kinase and the PI3Kinase 
pathway via the elastin receptor (Duca, Lambert et al. 2005). Blocking of either pathway with 
pharmacological inhibitors PD98059 (Erk/MAPK) or Wortmannin (PI3Kinase) had no effect on 
ELP induced proliferation (Figure 3.1). Hence, these experiments demonstrate that the interaction 
of ELPs with the elastin receptor is not responsible for ELP induced proliferation.  
 After ruling out the elastin receptor we focused on the possible role of cell surface heparan 
sulfate proteoglycans since several studies have shown that ELPs interact with them (Broekelmann, 
Kozel et al. 2005, Gheduzzi, Guerra et al. 2005, Tu and Weiss 2008). We pretreated the fibroblasts 
with Heparinase III, an enzyme that specifically cleaves cell surface heparan sulfates and Surfen a 
small molecule antagonist of heparan sulfate (Schuksz, Fuster et al. 2008). Indeed, Heparinase III 
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and Surfen showed 95% and 85% blockage of ELP induced fibroblast proliferation respectively 
(Figure 3.2) suggesting that the interaction of ELPs with cell surface heparan sulfates is responsible 
for ELP mediated proliferation.  
 Further downstream signaling pathway was also investigated, we used go6983, a pan 
protein kinase C (PKC) inhibitor to pretreat the fibroblasts. Interestingly, at lower concentration 
(500nM) of go6983, ELP was still able to induce proliferation, while at a higher concentration 
(1µM), this proliferative effect was reversed, suggesting that PKC δ and PKC ζ may be involved 
in this interaction. Further study is needed to confirm the responsible signaling pathway of ELP-
HSPG interaction. 
3.4.2 Mitogenic Potential of ELPs Can Be Controlled by Modulating ELP-HSPG 
Interactions through Sequence Modification 
Since, we discovered that HSPG interaction with ELP’s is responsible for ELP mediated 
proliferation we hypothesized that the mitogenic potential of ELPs can be controlled by 
modulating their interaction with HSPG. Previous work has suggested the presence of -strand is 
important for the interaction of proteins with heparan sulfates (Margalit, Fischer et al. 1993). Since 
during phase transition, ELP structure changes from random coils to β-turn (Hong, Isailovic et al. 
2003), we investigated the effect of phase transition on ELP induced cell proliferation. Monomer 
peptide VPGVG which has same sequence motif as ELP, doesn’t transition at physiological 
temperature. Indeed, without phase transition, the monomer failed to induce cell proliferation 
(Figure 3.5).  
Our data demonstrate clearly that the proliferative potential of ELPs is dependent on their 
phase transitioning properties. We further reasoned that ELP sequences having different transition 
properties will have varying proliferative potential. To prove this, we designed an ELP sequence 
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--- L10 containing 10 leucine having the same molecular weight as V40C2 (Table 1). Since leucine 
is more hydrophobic than valine or cysteine, L10 has a lower transition temperature than V40C2 
at the same concentration. Dynamic light scattering (DLS) showed that at 5 M concentration, 
V40C2 didn’t transition while L10 transitioned at about 350C (Figure 3.6b). At this concentration, 
V40C2 failed to induce cell proliferation; while L10 increased cell proliferation by 2.5 folds 
(Figure 3.6a). These data indicate that the proliferative potential of ELPs is directly dependent on 
their ability to transition. 
Heparan sulfate proteoglycans are highly negatively charged. So we reasoned that besides 
transition, ELP-HSPG interaction can be modulated by creating positively charged ELPs; thereby 
resulting in ELPs having differential proliferative potential. ELPs containing positively charged 
lysine (K10, Table 1) at the guest position were created. Indeed, K10 induced proliferation of 
fibroblasts at higher folds than V40C2 or L10 suggesting that the presence of charges induce a 
stronger proliferation response than the ability to transition (Figure 3.7a). Interestingly, at 
physiological temperature K10 doesn’t transition due to the presence of hydrophilic lysine residues 
(Figure 3.7b) suggesting that phase transition is not the only dominant mechanism of ELP 
mediated fibroblast proliferation.  
3.4.3 ELP Induced Matrix Metalloproteinase Induction via Elastin Receptor and Is 
Independent of Phase Transition or Charge 
Previous research has demonstrated that the GXXPG motif contained in tropoelastin 
induces pro-MMP1 expression (Moroy, Alix et al. 2005). Since ELP has the similar sequence 
motif VPGXG, we tested the induction of MMP1 gene by ELPs in fibroblasts using quantitative 
real time polymerase chain reaction (qRT-PCR). Indeed similar to elastin derived monomeric 
peptides, ELP significantly induced MMP1 expression in fibroblasts.  Interestingly, lactose 
Temperature (˚C) 
Temperature (˚C) 
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blocked the ELP induced MMP1 expression suggesting the involvement of the elastin receptor in 
MMP1 induction unlike proliferation. Furthermore, we investigated the effect of phase transition 
or charges in the induction of MMP-1 by ELPs. We found that the monomer VPGVG induced 
MMP1 induction suggesting that it is independent of the phase transition property of ELPs. 
Furthermore, while high concentrations of L10 and V40C2 (50 m) induced MMP-1 induction, 
lower concentrations of L10 (5 M) did not result in MMP-1 induction, unlike proliferation (Figure 
3.8). 
3.5 Discussion 
Current research on biomaterials mostly describes inert biomaterials that provide 
mechanical support or act as drug delivery vehicles carrying an active drug for tissue regeneration. 
The bioactivity of the biomaterials is typically achieved by the inclusion of an active drug or an 
active sequence that induces cellular response. However, our work suggests that the biomaterial 
backbone (VPGXG) is also capable of inducing fibroblast proliferation with no active biological 
signal embedded within. Thus, ELP based biomaterials are not only capable of providing 
mechanical support but also have biological activities conducive to fibroblast proliferation which 
is crucial for healing of different tissues.  
 Elastin derived peptides that are prepared by proteolytic degradation of -elastin or elastin 
based tissues have been shown to increase proliferation of arterial smooth muscle cells (Mochizuki, 
Brassart et al. 2002) and fibroblasts (Shiratsuchi, Ura et al. 2010) respectively. Since, these studies 
were done using a complex mixture of degradation products of elastin, the exact sequence or 
molecular weight of the species that induced proliferation could not be identified. On the other 
hand our work reports the induction of proliferation by a single elastin sequence with precise 
molecular weight, thus allowing us to identify the exact sequence responsible for proliferation. 
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Our work indicates that the model sequence (VPGVG)50 induced fibroblast proliferation. However, 
previous work has reported that the monomeric or polymeric form of this model sequence VPGVG 
created by solid peptide synthesis did not demonstrate any significant proliferative activity on 
fibroblasts (Tajima, Wachi et al. 1997). This could be attributed to the very low concentrations of 
ELP used in that study compared to our experiments. The concentration of ELP is directly related 
to their transition behavior, which seems to be critical for inducing fibroblast proliferation as 
demonstrated by our experiments. 
The observed mitogenic activity of ELPs is lost due to crosslinking or when they are 
immobilized on a solid substrate. This result explains why previous work performed with ELP 
hydrogels report no significant biological activity; since it involved chemically cross-linked ELP 
hydrogels leading to the loss of the mitogenic activity of ELPs (Nettles, Kitaoka et al. 2008, 
Hrabchak, Rouleau et al. 2010). Interestingly, the inability of the cells to internalize the cross-
linked ELP will not explain the loss in bioactivity since the induced proliferation was independent 
of ELP internalization. Crosslinking results in loss of ability of ELPs to toggle between aggregates 
or single monomeric forms, which may lead to the loss of the biological activity. Further studies 
are needed to investigate the exact role of cross-linking and its effect on the biological activity of 
ELPs.   
Our studies indicate that the interaction of ELPs with cell surface heparan sulfate 
proteoglycans (HSPGs) is responsible for the proliferation induced by ELPs. Although the 
interaction of the elastin sequence VPGXG with heparin and HSPGs has been demonstrated 
(Gheduzzi, Guerra et al. 2005, Tu and Weiss 2008) in several in vitro binding assays, no studies 
have reported that the interaction of ELPs with cell surface HSPG leads to cell proliferation or any 
biological activity by ELPs. Also, this finding is truly novel as previous studies involving the 
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mechanism of ELP-cell interactions leading to its biological activity primarily focused on the 
elastin receptor complex (ERC) (Duca, Blanchevoye et al. 2007, Antonicelli, Bellon et al. 2009). 
For example, elastin derived peptides have been shown to interact with the elastin receptor leading 
to MMP-1 induction in fibroblasts. Similar, to this study our work also shows induction of MMP-
1 activity by ELPs through the elastin receptor suggesting that ELPs also interact with the receptor. 
However, the observed mitogenic effect of ELPs is independent of this interaction and is dependent 
on HSPGs. Thus, these results indicate that ELPs affect several important processes for tissue 
regeneration namely inflammation, matrix remodeling (MMP-1 activity) and proliferation, via 
distinct receptors present on the cells. Furthermore, MMP-1 induction by ELPs was independent 
of the phase transition property unlike proliferation. Further studies are underway to elucidate the 
differences in ELP binding to these two receptors leading to activation of different pathways 
resulting in different bioactivity.  
The mitogenic activity of ELPs is closely related to their ability of phase transition. One 
possible explanation for this is that during phase transition, ELPs form β-strand structure, which 
has been reported as a common secondary structure for variety of proteins that interact with cell 
membrane bound HSPG (Hileman, Fromm et al. 1998). Thus, the phase transition of ELPs enables 
the interaction of ELPs with HSPG leading to fibroblast proliferation. Since, immobilization 
prevents the ELP chains to come together affecting their structural transition this may also explain 
the loss of bioactivity of ELPs due to crosslinking. We further demonstrate that it is possible to 
modulate the proliferative activity of ELPs by designing ELP sequences having different transition 
behavior. ELP sequences that transition easily by incorporation of hydrophobic leucine were more 
mitogenic. We further show modulation of this ELP interaction with HSPGs by inclusion of 
charged amino acids within the ELP sequence, since HSPGs are negatively charged. We show that 
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ELPs containing positively charged lysine residues were highly mitogenic compared ELPs 
containing no charged residues. These studies demonstrate a simple way of controlling the 
mitogenic activity of ELPs by simply including either hydrophobic amino acids affecting phase 
transition or charged amino acids. Controlling the mitogenic activity of ELPs in context to tissue 
regeneration is extremely crucial. Take chronic wound healing for example, little or no fibroblast 
proliferation leads to chronic wounds; while excessive fibroblast proliferation is also not desired 
as it leads to fibrosis (Rieder, Brenmoehl et al. 2007).  
In summary, our work demonstrates that the biological activity of ELPs can be modulated 
by simply tweaking their physical properties. Specifically, we show for the first time that ELPs 
induce fibroblast proliferation which is dependent on cell surface HSPGs. We further show that 
this interaction can be modulated by designing ELP sequences having different phase transition 
behavior or charge; thereby controlling the mitogenic activity of ELPs. Fibroblast proliferation 
and function is essential for granulation tissue formation in not only chronic wound healing but in 
healing of injuries of other tissues such as bone or neural tissue. Thus, ELP based materials with 
differential proliferative activity on fibroblasts can be designed and will have broad application in 
the development of therapeutics for tissue regeneration. 
 
 
Table 1 ELPs sequences and characterization 
ELP Sequence Charge 
V50 (VPGVG)50 Neutral 
V40C2 (VPGVG)40(VPGVGVPGVGVPGCGVPGVGVPGVG)2 Neutral 
L10 (VPGVGVPGVGVPGLGVPGVGVPGVG)10 Neutral 
K10 (VPGVGVPGVGVPGKGVPGVGVPGVG)10 Positive 
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Figure 3.1 ELP induced cell proliferation is not dependent on elastin receptor complex. Cells were 
starved for 24hrs and pre-blocked with different inhibitors lactose 5mM, PD98059 10 M and 
Wortmannin 100 nM. They were then treated with 50 M ELP for 48hrs in the presence of the 
inhibitors. Cell proliferation was evaluated using the BrdU assay. All the values are obtained from 
triplicate experiments and normalized to control. *= p< 0.05 when the indicated samples were 
compared. 
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Figure 3.2 ELP induced cell proliferation is dependent on HSPG. Cells were starved for 24hrs and 
pre-blocked with different inhibitors Heparinase III 20mIU or  surfen 10M. They were then 
treated with 50 M ELP for 48hrs in the presence of the inhibitors. Cell proliferation was evaluated 
using the BrdU assay. All the values are obtained from triplicate experiments and normalized to 
control. *= p< 0.05 when the indicated samples were compared. 
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Figure 3.3 PKC signaling pathway may be involved in the ELP induced proliferation. Cells were 
starved for 24hrs and pre-blocked with Go6983 500nM or 1µM. They were then treated with 50 
M ELP for 48hrs in the presence of the inhibitors. Cell proliferation was evaluated using the 
BrdU assay. All the values are obtained from triplicate experiments and normalized to control. *= 
p< 0.05 when the indicated samples were compared. 
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Figure 3.4(a) Syndecan 1 may be involved in ELP-cell interaction downstream signaling pathway. 
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Figure 3.4(b) Syndecan 1 is dominantly expressed in skin fibroblasts. 
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Figure 3.5 VPGVG monomer didn’t induce the proliferation.  ELPs were starved for 24hrs and 
then treated for 48 hrs with 50 M of ELP (V40C2) or the peptide VPGVG. Cell proliferation was 
evaluated using the BrdU assay. All the values are obtained from triplicate experiments and 
normalized to control. 
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Figure 3.6(a) Controlling ELP induced cell proliferation through sequence modification. Cells 
were starved for 24hrs then treated for 48 hrs. with 5M of ELPs. BrdU assay was performed for 
cell proliferation.  
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Figure 3.6(b) L10 transition before physiological temperature at 5M. ELPs were dissolved in 
PBS to 5M and phase transition was quantified using dynamic light scattering (DLS)All the 
values are obtained from triplicate experiments and normalized to control. *=p<0.05. 
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Figure 3.7(a) ELPs containing positively charged amino acids induce cell proliferation 
independent of phase transition. Cells were starved for 24hrs then treated for 48 hrs with either 
V40C2 or K10. BrdU assay was performed for cell proliferation. All the values are obtained from 
triplicate experiments and normalized to control *= P<0.05.  
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Figure 3.7(b) K10 didn’t transition before physiological temperature at 50M. V40C2 and K10 
were dissolved in PBS and phase transition was evaluated using dynamic light scattering. 
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Figure 3.8 ELPs induced MMP1 expression in fibroblasts is independent of phase transition. Cells 
were serum starved for 24hrs and then treated with either 5 or 50 M concentrations of the 
indicated ELPs. Total RNA was collected for qRT-PCR to quantify MMP-1 gene expression. All 
the values are obtained from triplicate experiments and normalized to control. *= indicates p<0.1, 
**= indicates p<0.05. 
 
 
 
 
 
 
 
 
 
(c) 
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Figure 3.9 Schematic of interaction mechanism of ELP induced cell proliferation. 
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CHAPTER 4: A PROTEASE RESISTANT FORMULATION FOR DELIVERY OF 
BIOACTIVE MOLECULES FOR TISSUE REGENERATION 
 
4.1 Introduction 
 Protein therapeutics have obtained numerous attention for past decade and already have a 
significant role in almost every field of medicine. Compare to small molecule drugs, protein 
therapeutics have several advantages such as high specificity, less likely to elicit immune response 
and shorter clinical development and FDA approval time (Leader, Baca et al. 2008). The 
development of recombinant DNA technique greatly helped the widespread of protein therapeutics 
through the availability of modification of the protein and potentially limitless quantity (Barton, 
Brady et al. 1991, Grabowski, Barton et al. 1995). 
In the field of regenerative medicine, proteins like growth factors and cytokines are often 
used to stimulate the proliferation, migration and differentiation of different cell type to promote 
the healing of skin tissue, bones and etc (Moura, da Silva et al. 2013, Liu, Ou et al. 2014, Valente 
and Ciavarella 2016). Platelet derived growth factor (PDGF) which stimulates fibroblasts 
proliferation has been approved by FDA for the treatment of diabetic ulcers (Smiell, Wieman et 
al. 1999). Other growth factors like epidermal growth factor (EGF), keratinocyte growth factor 
(KGF), vascular endothelial growth factor (VEGF) also have shown promising results in both in 
vitro and in vivo studies (Koria, Yagi et al. 2011, Barrientos, Brem et al. 2014, Johnson and Wang 
2015). However, there are still some problems hindering the translation of these growth factors 
from clinical research to FDA approved medicines. Tissue regeneration is a complex process that 
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depends on tightly regulated signaling molecules at exact times, locations, and concentrations 
(Clause and Barker 2013). Growth factors usually experience a short half-life after been delivered 
to the injury site due to excessive protease existed in the wounded area (Dinh, Braunagel et al. 
2015). Engineered delivery system for growth factor therapy is a very attractive way to modulate 
cell behavior. Encapsulation of growth factors in hydro gel is a common way of achieving 
controlled delivery. Rybalko and co-worker have done a delicate work to deliver SDF-1α and IGF-
I within a novel poly-ethylene glycol PEGylated fibrin gel matrix (Rybalko, Pham et al. 2015). 
Conjugation of growth factors to a stabilizing molecule is another way of extending half-life. Thi 
H. Nguyen and co-worker used a heparin-mimicking polymer conjugate to stabilize basic 
fibroblast growth factor (bFGF) (Nguyen, Kim et al. 2013). Poly(ethylene glycol) (PEG) is  
another stabilizing molecule which has been widely explored as a means to improve the half-lives 
of proteins (Wang, Cooke et al. 2013, Miao, Rao et al. 2014). PMP-D2 is a naturally occurring 
peptide derived from the brain and fat body of the insect Locusta Migratoria (Kellenberger, Ferrat 
et al. 2003). It has 35 residues which cross-linked by three disulfide bonds. PMP-D2 variant 
(R29L/K30M) has a strong inhibitory activity towards serine protease through increased binding 
affinity of P1 residue within the reactive site of the inhibitor (Kellenberger, Boudier et al. 1995).  
Elastin is a major component in connective tissue and may be beneficial for tissue 
regeneration. Elastin derived peptides which are short peptide pieces digested from tropoelastin 
have been showed to modulate cellular behavior of a variety of cell types such as fibroblasts and 
monocytes (Senior, Griffin et al. 1984), hepatocytes (Janorkar, Rajagopalan et al. 2008), smooth 
muscle cells (Mochizuki, Brassart et al. 2002), endothelial cells (Faury, Garnier et al. 1998) and 
keratinocytes (Fujimoto, Tajima et al. 2000). Specifically in fibroblasts that play a key role in 
regeneration, EDPs have been shown to induce proliferation and expression of several matrix 
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remodeling proteins such as collagenase (Brassart, Fuchs et al. 2001, Duca, Debelle et al. 2002). 
Elastin like peptides are synthetic peptide that are composed of repeated blocks of  (Val-Pro-Gly-
X-Gly)n, a sequence motif that derived from hydrophobic domain of tropoelastin. An interesting 
property of ELPs is their ability to undergo phase transition at transition temperatures. When the 
temperature is below their inverse transition temperature, also known as the lower critical solution 
temperature (LCST), they assume a random coil structure and are soluble in aqueous solution. 
However, at temperatures higher than the LCST, ELPs undergo an entropy driven self-assembly 
rendering them insoluble (Koria, Yagi et al. 2011). This property enables recombinant ELPs to be 
expressed in bacteria and rapidly purified using inverse temperature cycling (ITC). Genetic fusion 
of ELP with protein or peptide has been studied and proved to be a promising delivery method 
since it forms certain nanostructure and can be easily purified.  
Previously in our lab, we have created several recombinant growth factors fusion proteins 
with elastin like peptide including KGF-ELP and BMP-2-ELP which not only maintained ELP 
phase transition property but also retained growth factor bioactivity (Table 1). In this study, we 
have fabricated a fusion protein comprising of recombinant PMP-D2 variant and elastin like 
peptide (PMP-D2-ELP), mixed it with the growth factor fusions and allow them transition at 
physiological temperature to form multifunctional nanoparticles which may address the stability 
issue and improve delivery of different growth factors for tissue regeneration application. 
Currently, the golden standard animal model for studying of chronic wound healing is 
diabetic mice or rats (Ansell, Holden et al. 2012). They are the most widely used model, including 
genetically deficient type I diabetic mice, also known as non-obese diabetic (NOD) mice and type 
II diabetic mice which are leptin or leptin receptor knockout mice (Islam 2013). Although NOD 
mice do show a delayed wound healing process, they may not be a suitable model for diabetic foot 
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ulcers which are prevalent in type II diabetes (Keswani, Katz et al. 2004, Boulton 2008). Leptin 
receptor deficient mice become obese from around 6 weeks of age, and consequently develop type 
II diabetes. Research have shown that the wound repair has been markedly delayed (Tsuboi and 
Rifkin 1990, Ring, Scully et al. 2000). Many growth factors have been identified their therapeutic 
potential using this model (Greenhalgh, Sprugel et al. 1990, Kitano, Yoshimura et al. 2001, Bevan, 
Gherardi et al. 2004, Hardwicke, Hart et al. 2011), however, only PDGF-BB has successfully gone 
through the human trials and approved by FDA for treatment of diabetic foot ulcers suggesting the 
poor predictivity of the diabetic mice model. In human chronic wounds, excessive protease level 
is found in the area which break the balance between itself and growth factors and other signaling 
molecules, thus cause a delay of the formation of granulation tissue. Currently animal chronic 
wound models including diabetes model, ageing model, skin flap model, and pressure model all 
lack of the important property of excessive protease level in human chronic wounds. In this study, 
we created a chronic wound model using leptin receptor deficient mice incorporating with elastase 
treatment in hydrogel which significantly delayed the wound healing process. 
4.2 Materials and Methods 
4.2.1 Materials  
Human dermal fibroblasts (CRL-2522) were purchased from ATCC (Manassas, 4.2VA). 
PBS, FBS and DMEM were all purchased from life technologies. The restriction enzymes used 
for cloning were purchased from New England Biolabs (Ipswich, MA). The reagents for RT-PCR 
were purchased from Bio-Rad. 
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4.2.2 Generation of PMP-D2-ELP Plasmids and Expression of the Protein 
The PUC57 plasmids containing the PMP-D2 gene cassette were purchased from Genscript 
(Piscataway, NJ). V40C2 encoding genes were made using recursive direction ligation method as 
described previously (Meyer and Chilkoti 2002).  
The expression vector pET25b+ was digested with SfiI and dephosphorylated. Ligation 
was performed using linear pET25b+ vector and respective PMP-D2-ELP encoding gene cassettes.  
E.coil BLR cells were transformed with expression vector with PMP-D2-ELP encoding genes. For 
protein production, a starter culture of 75ml terrific broth medium was inoculated overnight and 
added to 1L culture the next day. After 16hrs of induction, bacterial cells were harvested by 
centrifugation at 40C, re-suspended in ice cold phosphate buffered saline (PBS). Cells were lysed 
on ice using sonication. Cell debris was removed by centrifugation at 40C followed by 
polyethyleneimine treatment (final concentration: 0.5% w/v) for DNA precipitation. After another 
centrifugation at 40C, the clear supernatant was heated up to 400C in water bath for 15min to 
transition the ELPs followed by centrifugation at 400C to pellet the ELPs. The ELP pellet was then 
dissolved in ice cold PBS followed by centrifugation at 40C to remove the insoluble impurities. 
This hot and cold spin cycle was then repeated twice for a total of three cycles. The final protein 
pellet was dissolved in deionized water and dialyzed overnight. The protein was then lyophilized 
and stored in a desiccator. 
4.2.3 Elastase Activity Assay 
Neutrophil elastase colorimetric drug discovery kit (ENZO) was used to test the inhibition 
activity of PMP-D2-ELP fusion protein against elastase. Lyophilized PMP-D2-ELP and ELP 
control were dissolved separately in PBS to make 10mg/ml stock concentration and 0.2mg/ml final 
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concentration was used in the assay. Elastase (2mU/µl) was diluted 1/90 in assay buffer for the 
experiment. Absorbance at 405 was read every minute from 0 to 20 minutes for each sample.  
4.2.4 Western Blot 
 Growth factor ELP fusion proteins (PDGF-ELP and BMP2-ELP) were dissolved in PBS 
to reach a concentration of 1mg/ml. They either mix with 0.2mg/ml of PMP-D2-ELP to form 
multifunctional nanoparticles then treated with 20mU/ml elastase or directly treated with 20mU/ml 
elastase for up to 2 hours. At time point 15 minutes, 30 minutes, 1 hour, and 2 hours, we collected 
the sample for each treatment and prepare for western blot analysis. 
4.2.5 BrdU Cell Proliferation Assay 
Human skin fibroblasts and A431 cells were cultured in 10 cm cell culture plates with 10% 
fetal bovine serum (Invitrogen, Grand Island, NY). 20,000 cells were plated in 48-well plate and 
were allowed to attach for 24 hours. After 24 hours, the cells were serum starved for another 24 
hours followed by treatment with different growth factor ELP fusion proteins (KGF-ELP and 
PDGF-ELP) for 48 hours. New DNA synthesis was quantified using the BrdU cell proliferation 
kit (BD Pharmingen, San Jose, CA) according to the manufacturer’s instruction. Briefly, cells were 
treated with BrdU for 24 hours. After 24 hours the cells were fixed and stained using a 
fluorescently tagged BrdU antibody. BrdU incorporation in the cells was evaluated using flow 
cytometry. 
 To explore the inhibition activity of PMP-D2-ELP against elastase and the multifunctional 
nanoparticles performance in elastase, we treated the cells with growth factor fusion proteins alone 
(1mg/ml) as positive control, growth factor fusion proteins (1mg/ml) mixing with elastase, and 
multifunctional nanoparticles (1mg/ml growth factor ELP fusion and 0.2 mg/ml PMP-D2-ELP) 
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with elastase. After 48 hours of treatments, cells were trypsinized and fixed, then treated with anti-
BrdU antibody. 7-AAD was used to stain the cell nucleus for cell cycle. 
4.2.6 Animals 
The mouse strain that we have chosen is B6.BKS-Leprdb from Jackson Laboratories. 
These mice are homozygous for the diabetes spontaneous mutation (Leprdb) and become 
identifiably obese around 3 to 4 weeks of age. They exhibit elevations of plasma insulin at 10 to 
14 days and of blood sugar at four to eight weeks. Moreover, wound healing in these mice is 
delayed. Hence, it is a good and well accepted model to study chronic diabetic wounds in the 
research community.  
4.2.7 Excisional Wounding of Skin 
Mice will be anesthetized using Isoflurane inhalation (3-4 % induction, 1-2 % maintenance) 
on a heating pad at 37C and anesthesia deemed sufficient when the animal lacks a contracting 
reflex in response to interdigital pinch and palpebral/eyeblink reflex. The eyes of the animal will 
be covered with medical ointment to prevent dryness. Hair will be removed from the dorsal area 
using electric clippers in an area away from the surgical site. The anesthetized animal would then 
be brought to the surgical site and the dorsum will be prepared by a three-fold alternating 
application of Betadine SCRUB and 70% alcohol solution. A 1cm x 1cm square area will be drawn 
with a black marker on the back of the animal using a template. The skin will be gently lifted up 
and cut along the marked boundary to generate a full-thickness skin defect on the dorsum. 100µl 
of fibrin gel containing 25mU/ml elastase will be administered into the wounds. The mice will 
then be dressed with a 2.5 cm x 2.5 cm piece of adherent silicone dressing (Tegaderm™) 
encompassing an area extending at least 1 cm beyond the wound boundaries. Animals will be 
single caged after the procedures and standard bedding will be used.  
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4.2.8 Post Procedure Observations 
Animals will be under continuous examination until they recover from the anesthesia as 
evidenced by the ability to maintain themselves in an upright position, and by assessment of the 
respiratory rate and response to visual, acoustic, and touch stimuli. Then, they will be returned to 
the animal housing area. After housing, animals will be observed every 12 hours for 72 hours then 
daily till 28 days. Animals with be euthanized at 21 days post wounding and tissue surrounding 
the wound area (including the wound) will be excised and collected for histological analysis. 
4.2.9 Statistical Analysis 
Cell proliferation assay results were expressed as normalized mean ± SEM to control. 
Statistical significance of the observed differences was evaluated by ANOVA: single factor 
whereas p value < 0.05 were considered significant (n=3). 
4.3 Results 
4.3.1 PMP-D2-ELP Inhibits Elastase Activity 
 After successfully purified PMP-D2-ELP using ITC, we tested the protease inhibition 
activity of the fusion protein using elastase activity assay. Human leukocyte elastase (HLE) is 
selected because it is the protease that found most abundant in skin chronic wounds. Indeed, PMP-
D2-ELP inhibited HLE activity by 76% (Figure 4.3), suggested that the fusion protein retained the 
protease inhibition activity of PMP-D2. Interestingly, the data showed that ELP by itself also 
inhibited HLE activity by 33%. Since elastin is a known substrate of elastase, competitive 
inhibition could be an explanation of this finding. 
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4.3.2 Multifunctional Nanoparticles Prevented Degradation of Growth Factors in HLE 
Environment 
 Next we the examined the stability of mNPs in HLE environment. Two growth factor 
fusion protein, BMP-2-ELP and PDGF-ELP were mixed at 5:1 ratio separately with PMP-D2-ELP 
to make mNPs. Then mNPs were incubated with HLE at 37 ˚C for different time points from 15 
minutes to 2 hours. The western blot data showed that for BMP-2-ELP, with or without PMP-D2-
ELP, there was an initial degradation, however with the help of PMP-D2-ELP, the mNPs were 
able the maintain stable after 2 hours; while the control BMP-2-ELP kept degrading.  For PDGF-
ELP, the mNPs kept almost 100% activity of PDGF after 2 hours; while the control was fully 
degrade by elastase after 30 minutes (Figure 4.4). This result clearly suggested that PMP-D2-ELP 
was able to prevent growth factor degradation from HLE. 
4.3.3 mNPs Retained Proliferative Activity of Growth Factors in vitro 
 To compare the bioactivity of the recombinant growth factors in mNPs and growth factor 
fusion protein alone with the existence of HLE, we performed cell proliferation assay. KGF-ELP 
and PDGF-ELP were used in this experiment since they are both crucial growth factors for skin 
wound healing. The responsive cell lines are A431 and fibroblasts respectively. To test KGF mNPs, 
we serum starved the cells for 24 hours and then added KGF-ELP, KGF-ELP with HLE, mNPs 
with HLE as treatment.  Indeed KGF-ELP alone induced cell proliferation by 2 folds, with HLE 
the proliferative effect has been reversed due to degradation; while mNPs restored KGF activity 
completely. PMP-D2-ELP had no effect on A431 cell as same as HLE (Figure 4.5a). 
 Similarly, for PDGF mNPs, we serum starved the fibroblasts for 24 hours and then added 
PDGF-ELP, PDGF-ELP with HLE, mNPs with HLE as treatment. Same pattern was found in 
proliferation data, PDGF mNPs was able to prevent degradation and induce fibroblast proliferation 
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by around 1.5 folds (Figure 4.5b). Both cell proliferation assays suggested that comparing to 
growth factor alone, mNPs was able to improve the stability and retain the bioactivity of growth 
factor with the existence of HLE. 
4.3.4 Excessive HLE Delayed the Healing of Full-Thickness Wound in Genetically Diabetic 
Mice 
 To evaluate the effect of excessive elastase on wound healing of genetically diabetic mice, 
we created a 1 cm ×1 cm full thickness wound on the dorsal area of the mouse. Elastase was treated 
on the wound with fibrin gel for either 14 days or 21 days. 15 days after the treatment, control 
wound closed about 80%; while for both 14-day and 21-day treatment wound closed about 50% 
(Figure 4.7c). Significant delay of wound healing was observed when wound treated with HLE. 
After 21 days, 14-day treatment wound and control both healed completely, while 21-day 
treatment wound had 30% wound area remain open showing that HLE didn’t cause permanent 
damage to the wound, the delay of the wound healing is reversible by removing elastase.  
4.4 Discussion 
 In this work we demonstrated the development of a formulation that preserving the 
bioactivity of different functional peptides and growth factors in excessive protease environment 
by incorporation of an elastase resistant peptide. Growth factors are crucial signaling molecules 
for tissue regeneration. The delivery of growth factors has been always the key to the successful 
clinical application. Currently the delivery methods of growth factors involve chemical 
conjugation and physical encapsulation (Koria 2012). However, for these methods, issues like 
growth factor release speed, the toxicity of the crosslinking agent and the correct balance between 
the factor dose and physical and chemical properties of the scaffold, which can regulate cell 
behavior are still require further investigation. 
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 The fusion PMP-D2-ELP inhibited elastase activity significantly which is in agreement 
with previous studies that ELP fusion protein not only maintain the ELP transition property but 
also retain the bioactivity of the functional group. One interesting finding of our experiment is that 
ELP by itself inhibited elastase activity by 33%.  ELP is a synthetic peptide that has a repeated 
sequence motif derived from the hydrophobic domain of tropoelastin which is a known substrate 
of elastase. This data suggested that ELP part of the fusion protein also has the potential to preserve 
the growth factor activity by attenuating elastase activity through competitive inhibition. 
 Our fusion multifunctional nanoparticles clearly showed inhibition of elastase activity and 
prevention of degradation of growth factors. Western blot data suggested that with the existence 
of high concentration of elastase, most growth factors go through a complete degradation within 2 
hours. This data explains why in chronic wound treatment, a daily dose of PDGF BB, the only 
FDA approved growth factor, is required. Interestingly, even though we mentioned that ELP has 
an inhibition activity towards elastase, the growth factor ELP fusion proteins were almost degraded 
completely within 2 hours, suggesting that an elastase resistant peptide is needed in the mNPs. 
 In wound healing process, fibroblasts and epithelial cells are two important cell types 
involved, growth factors like KGF and PDGF are often used to induce the proliferation of these 
cells. From our data, growth factors were able to induce cell proliferation with the existence of 
elastase with the help of PMP-D2-ELP. Interestingly, here ELP fusion protein maintained phase 
transition property which allowed rapid expression and purification of large quantity of these 
proteins using inverse transition cycling (ITC). Moreover, this controllable transition behavior 
allowed ELP fusion proteins with different functional group self-assemble and form nanoparticles. 
These particles not only serves as drug delivery vehicle but also the drug itself which targets 
different cell types and signaling molecules. Several advantages of our multifunctional 
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nanoparticles comparing to other growth factor delivery methods include first of all, it doesn’t 
require extra engineering procedures like physical encapsulation, release and chemical 
crosslinking; second, instead just induce the proliferation of certain cell type, the mNP could target 
multiple cell types using different functional peptides, this is especially important to chronic 
wound healing which is considered a complex process involved sequential  phases that promoted 
by many cell types and ECM proteins. 
 Currently diabetic mouse model for studying chronic wound healing has several limitations 
such as the protease level is significant lower comparing to human chronic wound environment, 
and the healing process is also much faster, usually takes about 21 days due to contraction (Figure 
4.6). Here we tried to develop a new chronic wound model by treating elastase onto the wound 
with fibrin gel. The wound closure was significantly delayed with the treatment of elastase. 
Interestingly, after treated the wound for 14 days with elastase, we took out the treatment, the 
wound closed completely by day 21, and histology showed full re-epithelialization. This suggested 
that the delay of wound closure effect is reversible, elastase didn’t alter any cellular behavior 
permanently. This has been also proved in the cell proliferation assay experiment. Also, an 
interesting observation during the experiment is that the delay of the wound healing process is 
related to the yellow secretion which only found in the treatment wounds. One possible explanation 
is that the inflammatory phase had been prolonged by elastase treatment. Further investigation is 
needed to elucidate the mechanism of this delayed healing process. 
 In summary, we developed a multifunctional nanoparticle that comprised of PMP-D2-ELP 
fusion protein and different functional peptide ELP fusion proteins to preserve the bioactivity of 
the functional group with the existence of elastase. These heterogeneous particles will be beneficial 
for the delivery of combination therapy to solve multiple problems that often existed in chronic 
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wound healing or other tissue regeneration process. We also tested a new animal chronic wound 
model by increasing the local elastase concentration to mimic human chronic wound. The healing 
process has been delayed significantly. The development of this chronic wound model may help 
the translation of therapeutics that tested in animal research to clinical approved drug. 
 
 
Table 2 ELP fusion proteins sequences and molecular weight. 
ELP fusion 
protein 
Sequence Molecular 
Weight  
PMP-D2-ELP EEKCTPGQVKQQDCNTCTCTPTGVWGCTLM
GCQPA 
(VPGVG)40(VPGVGVPGVGVPGCGVPGVGVPG
VG)2 
24 KDa 
PDGF-ELP SLGSLTIAEPAMIAECKTRTEVFEISRRLIDRTN
ANFLVWPPCVEVQRCSGCCNNRNVQCRPTQV
QLRPVQVRKIEIVRKKPIFKKATVTLEDHLAC
KCETVAAARPVT 
(VPGVG)40(VPGVGVPGVGVPGCGVPGVGVPG
VG)2 
32 KDa 
BMP2-ELP HGVGQAKHKQRKRLKSSCKRHPLYVDFSDVG
WNDWIVAPPGYHAFYCHGECPFPLADHLNST
NHAIVQTLVNSVNSKIPKACCVPTELSAISMLY
LDENEKVVLKNYQDMVVEGCGCRVP 
(VPGVG)40(VPGVGVPGVGVPGCGVPGVGVPG
VG)2 
33.5 KDa 
KGF-ELP CNDMTPEQMATNVNCSSPERHTRSYDYMEG
GDIRVRRLFCRTQWYLRIDKRGKVKGTQEMK
NNYNIMEIRTVAVGIVAIKGVESEFYLAMNKE
GKLYAKKECNEDCNFKELILENHYNTYASAK
WTHNGGEMFVALNQKGIPVRGKKTKKEQKT
AHFLPMAIT 
(VPGVG)40(VPGVGVPGVGVPGCGVPGVGVPG
VG)2 
39 KDa 
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Figure 4.1 Schematic of a multifunctional nanoparticle. Fusion proteins comprising of different 
functional domains (yellow or red) self-assemble into a multifunctional nanoparticle. 
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Figure 4.2 Generation of PDGF-ELP fusion peptides. (a) Gene encoding PDGF was cloned in 
frame with the gene encoding for the elastin cassette. (b) The indicated samples were run on a SDS 
PAGE gel and stained with simply safe blue stain. Lane 1– Bacterial Lysate, Lane 2 – Purified 
PDGF-ELP. (c) The corresponding gel was then subjected to western blot with a monoclonal 
PDGF antibody. Lane 1 – Bacterial Lysate, Lane 2 – Purified KGF-ELP, Lane 3 – Ladder. (d) 
PDGF-ELP induced proliferation of human fibroblasts similar to recombinant PDGF. ** = P<0.05 
when compared to control (n=5). 
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Figure 4.3 PMP-D2-ELP fusion protein retained PMP-D2 variant bioactivity. Elastase (2mU/µl) 
was diluted 1/90 in assay buffer for the experiment. Absorbance at 405 was read every minute 
from 0 to 20 minutes for each sample. 
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Figure 4.4 Western blot shows mNPs preserved growth factors from degradation. Growth factor 
ELP fusion proteins (PDGF-ELP and BMP2-ELP) were dissolved in PBS to reach a concentration 
of 1mg/ml. They either mix with 0.2mg/ml of PMP-D2-ELP to form multifunctional nanoparticles 
then treated with 20mU/ml elastase or directly treated with 20mU/ml elastase for up to 2 hours. At 
time point 15 minutes, 30 minutes, 1 hour, and 2 hours, we collected the sample for each treatment 
and prepare for western blot analysis. 
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Figure 4.5(a) mNPs retained KGF proliferative activity. 20,000 cells were plated in 48-well plate 
and were allowed to attach for 24 hours. After 24 hours, the cells were serum starved for another 
24 hours followed by treatment with PDGF-ELP fusion proteins for 48 hours. New DNA synthesis 
was quantified using the BrdU cell proliferation kit. 
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Figure 4.5(b) mNPs retained PDGF proliferative activity. 20,000 cells were plated in 48-well plate 
and were allowed to attach for 24 hours. After 24 hours, the cells were serum starved for another 
24 hours followed by treatment with PDGF-ELP fusion proteins for 48 hours. New DNA synthesis 
was quantified using the BrdU cell proliferation kit. 
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Figure 4.6 Type II diabetes mice model (Leptin knockout).  
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Figure 4.7(a) Elastase treatment delayed the healing process in diabetic mice wounds. 1 cm ×1 cm 
full thickness wound was created on the dorsal area of the mouse. Elastase was treated on the 
wound with fibrin gel for either 14 days or 21 days.  
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Figure 4.7(b) Elevated HNE levels block healing of diabetic wounds. Full thickness wounds were 
treated either with vehicle (control) or with HNE (0.5 U/ml) every day. The HNE activity was 
measured in the wound fluid using HNE substrate MeOSuc-AAPV-pNA. The HNE activity was 
normalized to control. Two individual measurements of protease activity are shown. 
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Figure 4.7(c) Quantification of wound closure. Pictures of wounds were taken every other day. 
Area of the wounds was analysed using imageJ. 
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Figure 4.8 Histology of PMP-D2-ELP on diabetic mice wound showed that it didn’t affect the 
healing process. 
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Figure 4.9 ELP stays in diabetic mice wounds for 2 days. Full thickness wounds were treated biotin 
labeled ELP. Mice were euthenized at day 2, 4, and 7 for histology study. Backgroud cells were 
stained with hoechst dye.  
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CHAPTER 5: SUMMARY AND CONCLUSIONS 
 
5.1 Summary and Conclusions 
 In this dissertation, I have shown that the regulation of the proliferative activity of ELP on 
fibroblasts through the manipulation of phase transition and its application in chronic wound 
healing. An interesting property of ELPs is their ability to undergo phase transition at transition 
temperatures. When the temperature is below their inverse transition temperature, also known as 
the lower critical solution temperature (LCST), they assume a random coil structure and are soluble 
in aqueous solution. However, at temperatures higher than the LCST, ELPs undergo an entropy 
driven self-assembly rendering them insoluble. This physical property of ELP are dependent on 
the chain length and the chosen amino acid at the guest residue position. In our study, we 
investigated the potential bioactivity of ELP that could be beneficial for tissue regeneration. Indeed, 
we found out that ELP induces fibroblasts proliferation through interaction with HSPG, which is 
a complete new mechanism comparing to Elastin receptor for EDP-cell interaction. We further 
found out that the ELP fibroblast interaction is driven by the secondary structure change which is 
caused by phase transition. Consequently, we are able to control this proliferative activity the same 
way as we regulating ELP physical property, through the chain length and guest residues. Previous 
studies have shown that growth factor ELP fusion proteins not only could retain their phase 
transition property but also they are able to preserve the biological activity of the growth factors. 
However in chronic wound treatment, a delivery method is needed for growth factors to stay active 
in the presence of excessive protease. Here, we have created PMP-D2-ELP fusion protein which 
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can form heterogeneous multifunctional nanoparticles when mixed with other growth factor ELP 
fusion proteins. The inhibition activity of PMP-D2 allow growth factors retain their activity in the 
presence of elastase. Also we have developed a modified animal chronic wound model represents 
a quick and easy approach to re-create the HNE levels similar to human chronic wounds and block 
healing and can be used as an initial screening tool to test the efficacy of the proposed 
multifunctional NPs. 
 In chapter 2, we have demonstrated ELP induces the proliferation and mmp-1 expression 
of fibroblasts. Further we showed that these two functions of ELP were achieved through different 
interaction mechanism. ELP induced MMP-1 expression is through binding with elastin receptor 
complex similar to EDP-cell interaction; while ELP induced proliferation is close related to its 
phase transition property and is through HSPG. Crosslinking reversed the induced proliferation 
suggesting that the structure change associated with phase transition is crucial to this proliferative 
effect. 
 In chapter 3, our work demonstrates that the biological activity of ELPs can be modulated 
by simply tweaking their physical properties. Specifically, we show for the first time that ELPs 
induce fibroblast proliferation which is dependent on cell surface HSPGs. We further show that 
this interaction can be modulated by designing ELP sequences having different phase transition 
behavior or charge; thereby controlling the mitogenic activity of ELPs. Fibroblast proliferation 
and function is essential for granulation tissue formation in not only chronic wound healing but in 
healing of injuries of other tissues such as bone or neural tissue. Thus, ELP based materials with 
differential proliferative activity on fibroblasts can be designed and will have broad application in 
the development of therapeutics for tissue regeneration. 
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 In chapter 4, we developed a multifunctional nanoparticle that comprised of PMP-D2-ELP 
fusion protein and different functional peptide ELP fusion proteins to preserve the bioactivity of 
the functional group with the existence of elastase. These heterogeneous particles will be beneficial 
for the delivery of combination therapy to solve multiple problems that often existed in chronic 
wound healing or other tissue regeneration process. We also tested a new animal chronic wound 
model by increasing the local elastase concentration to mimic human chronic wound. The healing 
process has been delayed significantly. The development of this chronic wound model may help 
the translation of therapeutics that tested in animal research to clinical approved drug. 
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Appendix A: List of Abbreviations 
7-AAD 7-Aminoactinomycin D 
AGRP  Agouti related peptide 
AKT Protein kinase B 
ANOVA Analysis of variance 
BMP-2 Bone morphogenetic protein 2 
Brdu  Bromodeoxyuridine 
cDNA  Complimentary Deoxyribonucleic acid 
DI Water Deionized water 
DLS  Dynamic light scattering 
DNA  Deoxyribonucleic acid 
EBP  Elastin binding protein 
ECM  Extracellular matrix 
EDP  Elastin derived peptides 
EDTA  Ethylenediaminetetraacetic acid 
EGF  Epidermal growth factor 
ELISA  Enzyme-Linked Immunosorbent Assay 
ELP  Elastin like peptides 
ERC  Elastin receptor complex 
ERK  Extracellular signal-regulated kinases 
FBS Fetal bovine serum 
FDA Food and Drug Administration 
FGF Fibroblast growth factor 
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FITC Fluorescein isothiocyanate 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
Gly Glycine 
H2O2 Hydrogen peroxide 
HLE Human leukocyte elastase 
HSPG Heparan sulfate proteoglycan 
IGF Insulin-like growth factor 
ITC Inverse temperature cycling 
KCPS Kilo count per second 
KDa Kilo Dalton 
KGF Keratinocyte growth factor 
LCST Lower critical solution temperature 
MAPK Mitogen-activated protein kinases 
MMP Matrix metalloproteinase 
mNP Multifunctional nanoparticle 
NOD Non-obese Diabetes 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PDGF Platelet-derived growth factor 
PEG Poly(ethylene glycol) 
PI3K Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PKC Protein kinase C 
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Pro Proline 
RNA Ribonucleic acid 
RT Room temperature 
RT-PCR Real time-Polymerase chain reaction 
SEM Standard error of the mean 
SDC Syndecan 
SDS Sodium dodecyl sulfate 
TIMP-1 Tissue inhibitor of metalloproteinase 
Tt Transition temperature 
Val Valine 
VEGF Vascular endothelial growth factor 
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